Danielle Dubin is a Dermatology physician. OpenAlex indexes 42 publications with 755 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3 SW 129th Ave Ste 100
Pembroke Pines, FL 330271778
Telephone
866-400-3376Provider last certified this registry record 28 May 2026.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20256 payments
- ABBVIE INC.Program year202515 payments
- Galderma Laboratories, L.P.Program year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
36%Azole Antifungal36%Ketoconazole100%Part D≥25 patientsSensory organs
25.5%Corticosteroid25.5%Clobetasol Propionate59%Hydrocortisone42%Part D≥14 patientsDermatology
22.4%alpha-Hydroxy Acid8.1%Ammonium Lactate100%Part D<11 patientsCorticosteroid7.5%Triamcinolone Acetonide100%Part D≥12 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Bullous pemphigoid: A practical approach to diagnosis and management in the modern era
Journal of the American Academy of Dermatology
2025 - 64626 Identification of Predictive Hematologic Biomarkers for Early Detection of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome
Journal of the American Academy of Dermatology
2025 - Use of Oral Sarecycline as Monotherapy and in Combination With Topical Treatments in Patients With Acne: A Post-Hoc Analysis of Results From the Patient Reported Outcomes for Sarecycline Effectiveness and Safety (PROSES), a Single-Arm Prospective Cohort Study
SKIN The Journal of Cutaneous Medicine
2025 - Dupilumab to treat drug reaction with eosinophilia and systemic symptoms: A case series
The Journal of Allergy and Clinical Immunology In Practice
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Hywel C Williams
University of Nottingham
Mohsen Afarideh, MD, MPH
Mayo Clinic
Brigitte Dréno
Centre National de la Recherche Scientifique
Giovanni Damiani
University of Milan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”